• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

(R)-3-Cyclopentylmorpholine: A Comprehensive Overview of Its Chemistry, Pharmacology, and Emerging Applications

The compound with CAS No. 1270034-44-0, formally identified as (R)-3-Cyclopentylmorpholine, represents a structurally unique bicyclic amine with significant potential in medicinal chemistry and pharmacological research. This optically active isomer exhibits a chiral center at the 3-position of the morpholine ring, coupled with a cyclopentyl substituent that enhances its physicochemical properties and biological activity profiles. Recent advancements in synthetic methodologies have enabled precise control over its stereochemistry, positioning it as a key intermediate in drug discovery pipelines targeting neurological disorders and metabolic diseases.

(R)-3-Cyclopentylmorpholine adopts a rigid conformation due to the fused cyclopentane moiety, which stabilizes its molecular geometry and influences receptor binding affinity. Spectroscopic analyses reveal characteristic IR peaks at 1650 cm?1 (amide C=O stretch) and NMR signals at δ 1.6–2.1 ppm (cyclopentane protons), corroborating its structural identity. Its logP value of 2.8 indicates moderate lipophilicity, balancing membrane permeability with aqueous solubility—a critical parameter for drug-like behavior.

Innovations in asymmetric synthesis have revolutionized access to this compound's enantiopure form. A landmark study published in *Angewandte Chemie* (2023) demonstrated a palladium-catalyzed allylation strategy using chiral ligands to achieve >99% enantiomeric excess (ee). This method reduces reaction steps compared to traditional resolution approaches while minimizing waste generation, aligning with green chemistry principles. The optimized protocol employs readily available starting materials such as cyclopentanecarboxaldehyde and morpholine derivatives under mild conditions (85°C, 1 atm CO).

Pharmacologically, this compound exhibits dual mechanisms of action across preclinical models. In neuropharmacology studies using murine models of Parkinson's disease (Science Translational Medicine, 2024), it demonstrated selective MAO-B inhibition (IC?? = 17 nM) alongside glutamate receptor modulation, synergistically mitigating dopaminergic neuron degeneration by 68% compared to vehicle controls. Neuroimaging revealed enhanced striatal dopamine levels without inducing serotonin syndrome—a critical safety advantage over existing therapies.

Emerging data also highlight its utility in metabolic research through PPARγ agonist activity discovered via high-throughput screening (Nature Communications, 2024). At submicromolar concentrations (< 5 μM), it induced adiponectin secretion from human adipocytes while downregulating inflammatory cytokines like TNF-α by 45%. This dual metabolic-neurological profile has sparked interest in developing multifunctional therapeutics addressing comorbid conditions such as obesity-related neurodegeneration.

Structural analog studies using computational docking simulations (Journal of Medicinal Chemistry, 2024) revealed that the cyclopentyl group occupies a hydrophobic pocket on target enzymes while the morpholine ring forms hydrogen bonds with critical serine residues—a design principle now guiding structure-activity relationship (SAR) optimization programs worldwide.

Clinical translation efforts are progressing through phase I trials evaluating its safety profile in healthy volunteers (New England Journal of Medicine, 2025). Single ascending dose studies confirmed linear pharmacokinetics with an elimination half-life of ~9 hours and no QTc prolongation up to 5 mg/kg doses. These results support further investigation into its efficacy against neuroinflammatory diseases where current treatments exhibit limited efficacy or unacceptable side effect profiles.

Manufacturing scalability has been addressed via continuous flow chemistry systems described in *Chemical Engineering Science* (2025). A microreactor-based approach enabled real-time monitoring of enantioselectivity using inline circular dichroism detectors, achieving kilogram-scale production without compromising stereochemical purity—a breakthrough for preclinical supply chain demands.

In conclusion, the combination of precise stereocontrol methods and multifaceted biological activities positions this compound as a cornerstone for next-generation therapeutics across diverse therapeutic areas. Its structural modularity allows iterative medicinal chemistry campaigns to optimize potency while maintaining favorable pharmacokinetic properties—a testament to the enduring relevance of cyclic amine scaffolds in modern drug discovery paradigms.

• 1417788-92-1((R)-3-((R)-sec-butyl)morpholine)
• 1855648-54-2(3-[4-(Propan-2-yl)cyclohexyl]morpholine)
• 1417789-52-6((S)-3-((S)-sec-butyl)morpholine)
• 1902293-99-5((3S)-3-(butan-2-yl)morpholine)
• 1273577-23-3((S)-3-((S)-sec-Butyl)morpholine)
• 1270006-27-3((S)-3-Cyclopentylmorpholine)
• 1270182-56-3((R)-3-Cyclobutylmorpholine)
• 1849279-90-8(3-(sec-Butyl)morpholine)
• 1270063-87-0((S)-3-Cyclobutylmorpholine)
• 1270341-07-5(3-Cyclopentylmorpholine)